BeiGene beefs up PD-1 data with positive PhIII results for tislelizumab, this time in metastatic NSCLC

BeiGene has been angling to disrupt the PD-1 market for quite some time, and on Tuesday appeared to take one step closer.

The Chinese biotech announced that a Phase III study evaluating its PD-(L)1 checkpoint inhibitor tislelizumab in metastatic non-small cell lung cancer met its primary endpoint of overall survival. BeiGene didn’t provide numbers or p-values with Tuesday’s results, but noted that this was the drug’s third Phase III in NSCLC to go positive at the interim readout.